Real Time Touch

new TOP 200 Companies filing patents this week

new Companies with the Most Patent Filings (2010+)

Real Time Touch

Rsem Limited Partnership patents

Recent patent applications related to Rsem Limited Partnership. Rsem Limited Partnership is listed as an Agent/Assignee. Note: Rsem Limited Partnership may have other listings under different names/spellings. We're not affiliated with Rsem Limited Partnership, we're just tracking patents.

ARCHIVE: New 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009 | Company Directory "R" | Rsem Limited Partnership-related inventors

Novel minor histocompatibility antigens and uses thereof

Novel minor histocompatibility antigens (MiHAs) are described. These novel MiHAs were selected based on two features: (i) they are encoded by loci with a minor allele frequency (MAF) of at least 0.05; and (ii) they have adequate tissue distribution. Compositions, nucleic acids and cells related to these novel MiHAs are... Rsem Limited Partnership

Inhibition of sema3a in the prevention and treatment of ocular hyperpermeability

Described herein is a method of preventing or treating ocular vascular hyperpermeability including macular edema, in a subject comprising inhibiting Sema3A activity. Also disclosed are compositions and their use for preventing or treating Sema3A-dependent ocular vascular hyperpermeability.... Rsem Limited Partnership

Markers of poor prognosis acute myeloid leukemias (amls) and uses thereof

Genes exhibiting specific mutational and/or transcriptional patterns in poor prognosis AMLs, such as EVI1-rearranged acute myeloid leukemias (EVI1-r AMLs), relative to other types of AMLs and/or normal CD34+ cells, are disclosed. The use of these mutational and/or transcriptional patterns, for example the expression level of the PRKC Apoptosis WT1 Regulator... Rsem Limited Partnership

Compositions and methods for treating and preventing inflammation

The present invention provides novel compounds compositions and methods for (i) treating or preventing inflammation; and (ii) preventing or reducing hyperactivation of innate immune response, by inhibiting NRP1-dependent cell-signaling. Also provided are compounds, composition, and methods of specifically inhibiting SEMA3A-mediated cell signaling.... Rsem Limited Partnership

ARCHIVE: New 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009


This listing is an abstract for educational and research purposes is only meant as a recent sample of applications filed, not a comprehensive history. is not affiliated or associated with Rsem Limited Partnership in any way and there may be associated servicemarks. This data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for Rsem Limited Partnership with additional patents listed. Browse our Agent directory for other possible listings. Page by